The World Health Organization (WHO) today announced the flu vaccine strain recommendations from its advisory group for the Southern Hemisphere's 2025 season. The WHO makes these recommendations twice yearly, once for each hemisphere, and they are used by the national vaccine regulatory agencies and pharmaceutical companies to develop flu vaccines for the following influenza season, the WHO said.
"The periodic update of viruses contained in influenza vaccines is necessary for the vaccines to be effective due to the constant evolving nature of influenza viruses, including those circulating and infecting humans," the WHO said.
New H3N2 strain
Mimicking last year's recommendation, the WHO recommends manufacturers produce trivalent (three-strain) vaccines for use in the 2025 Southern Hemisphere influenza season, given that one of the influenza B strains used in quadrivalent (four-strain) vaccines hasn't been detected in years. The 2009 H1N1 recommendations remain the same as last year's, as do the B/Victoria lineage recommendations, but the H3N2 component has changed.
For egg-based vaccines, the experts recommend an A/Victoria/4897/2022 (H1N1)pdm09-like virus; an A/Croatia/10136RV/2023 (H3N2)-like virus; and a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.
For cell-culture vaccines, they recommend an A/Wisconsin/67/2022 (H1N1)pdm09-like virus; an A/District of Columbia/27/2023 (H3N2)-like virus; and a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.
For quadrivalent vaccines, the recommendation is unchanged from last year, a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
The periodic update of viruses contained in influenza vaccines is necessary for the vaccines to be effective due to the constant evolving nature of influenza viruses.
The recommendations today do not deviate from the WHO's February recommendations for Northern Hemisphere flu vaccines.